Financial Comparison: Lexicon Pharmaceuticals (NASDAQ:LXRX) and The Competition

Lexicon Pharmaceuticals (NASDAQ: LXRX) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Lexicon Pharmaceuticals to related companies based on the strength of its earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Lexicon Pharmaceuticals and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lexicon Pharmaceuticals 0 1 4 0 2.80
Lexicon Pharmaceuticals Competitors 956 3406 11909 239 2.69

Lexicon Pharmaceuticals currently has a consensus price target of $28.50, indicating a potential upside of 188.17%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.45%. Given Lexicon Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Lexicon Pharmaceuticals is more favorable than its competitors.

Insider & Institutional Ownership

49.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.8% of Lexicon Pharmaceuticals shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Lexicon Pharmaceuticals has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals’ competitors have a beta of 2.51, suggesting that their average stock price is 151% more volatile than the S&P 500.


This table compares Lexicon Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lexicon Pharmaceuticals -165.69% -111.68% -34.02%
Lexicon Pharmaceuticals Competitors -6,408.50% -83.97% -35.60%

Earnings & Valuation

This table compares Lexicon Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Lexicon Pharmaceuticals $83.34 million -$141.42 million -7.79
Lexicon Pharmaceuticals Competitors $290.27 million $35.99 million 53.02

Lexicon Pharmaceuticals’ competitors have higher revenue and earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


Lexicon Pharmaceuticals competitors beat Lexicon Pharmaceuticals on 8 of the 13 factors compared.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development. XERMELO is an orally-delivered small molecule compound approved by the Food and Drug Administration (FDA) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. It is developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound that it is developing for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound that the Company is developing for the treatment of neuropathic pain.

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply